Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a second commercial payer agreement for TONMYA, its fibromyalgia treatment, effective June 1, 2026. The agreement with a group purchasing organization provides coverage for approximately 17 million additional U.S. commercial lives, representing about 10% of the roughly 177 million commercial lives in the U.S.

With this second agreement, TONMYA now has commercial coverage for approximately 52 million U.S. lives, representing about 29% of total commercial lives in the U.S. The company announced its first commercial coverage agreement on May 6, 2026, which provided access to approximately 35 million U.S. commercial lives.

TONMYA is available in most states under Medicaid, representing approximately 75 million lives in total. Discussions with Medicare continue to advance, according to the company's press release.

The drug received FDA approval on August 15, 2025, for treating fibromyalgia in adults. TONMYA is a sublingual tablet formulation of cyclobenzaprine hydrochloride and represents the first new prescription medicine approved for fibromyalgia in more than 15 years.

"TONMYA's coverage by two leading GPOs is an important milestone in expanding patient access in the early phase of our commercial launch," said Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals.

Fibromyalgia affects more than 10 million adults in the U.S., predominantly women. The chronic pain disorder causes symptoms including widespread pain, nonrestorative sleep, fatigue, and morning stiffness.

Tonix offers a savings program for eligible, commercially insured patients through local pharmacies and digital pharmacy services. The company's patents are expected to provide TONMYA with U.S. market exclusivity until 2034.